Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial

• Published in: Haematologica (Roma) Vol. 999; no. 1
• Main Authors: Puig, Noemí, Agulló, Cristina, Contreras, Teresa, Pérez, José-Juan, Aires, Irene, Calasanz, María-José, García-Sanz, Ramón, Castro, Sergio, Martínez-López, Joaquín, Rodríguez-Otero, Paula, González-Calle, Verónica, González, Marta S, Oriol, Albert, Gutiérrez, Norma C, Ríos-Tamayo, Rafael, Rosiñol, Laura, Álvarez, Miguel-Ángel, Bargay, Joan, González-Rodríguez, Ana-Pilar, Alegre, Adrián, Escalante, Fernando, Iñigo, María-Belén, De la Rubia, Javier, Teruel, Ana-Isabel, De Arriba, Felipe, Palomera, Luis, Hernández, Miguel T, López-Jiménez, Javier, Reinoso, Marta, García-Mateo, Aránzazu, Ocio, Enrique M, Bladé, Joan, Lahuerta, Juan-José, Cedena, María-Teresa, Paiva, Bruno, Miguel, Jesús F San, Mateos, María-Victoria
• Format: Journal Article
• Language: English
• Published: Italy Ferrata Storti Foundation 11.07.2024
• ISSN: 0390-6078; 1592-8721; 1592-8721
• DOI: 10.3324/haematol.2024.285742

The value of quantitative immunoprecipitation mass spectrometry (QIP-MS) to identify the M-protein is being investigated in patients with monoclonal gammopathies but no data are yet available in high-risk smoldering myeloma (HRsMM). We have therefore investigated QIP-MS to monitor peripheral residual disease (PRD) in 62 HRsMM patients enrolled in the GEM-CESAR trial. After 24 cycles of maintenance, detecting the M-protein by MS or clonal plasma cells by NGF identified cases with a significantly shorter median PFS (mPFS; MS: not reached vs 1,4 years, p=0.001; NGF: not reached vs 2 years, p=0.0002) but reaching CR+sCR did not discriminate patients with different outcome. With NGF as a reference, the combined results of NGF and MS showed a high negative predictive value (NPV) of MS: 81% overall and 73% at treatment completion. When sequential results were considered, sustained negativity by MS or NGF was associated with a very favorable outcome with a mPFS not yet reached vs 1.66 years and 2.18 years in cases never attaining PRD or minimal residual disease (MRD) negativity, respectively. We can thus conclude that 1) the standard response categories of the IMWG do not seem to be useful for treatment monitoring in HRsMM patients, 2) MS could be used as a non-invasive, clinical valuable tool with the capacity of guiding timely bone marrow evaluations (based on its high NPV with NGF as a reference) and 3) similarly to NGF, sequential results of MS are able identify a subgroup of HRsMM patients with long-term disease control. This study was registered at www.clinicaltrials.gov (ClinicalTrials.gov identifier: NCT02415413).